WO2013177478A3 - Treatment method - Google Patents

Treatment method Download PDF

Info

Publication number
WO2013177478A3
WO2013177478A3 PCT/US2013/042556 US2013042556W WO2013177478A3 WO 2013177478 A3 WO2013177478 A3 WO 2013177478A3 US 2013042556 W US2013042556 W US 2013042556W WO 2013177478 A3 WO2013177478 A3 WO 2013177478A3
Authority
WO
WIPO (PCT)
Prior art keywords
muscle
prolyl
damage
inventors
hydroxylase
Prior art date
Application number
PCT/US2013/042556
Other languages
French (fr)
Other versions
WO2013177478A2 (en
Inventor
Samuel E. HONEYCUTT
Alan James Russell
Henning Fritz KRAMER
Original Assignee
Glaxosmithkline Intellectual Property (No.2) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property (No.2) Limited filed Critical Glaxosmithkline Intellectual Property (No.2) Limited
Publication of WO2013177478A2 publication Critical patent/WO2013177478A2/en
Publication of WO2013177478A3 publication Critical patent/WO2013177478A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to methods of treating muscle injury, tendon damage, or a muscle degenerative disorder by administering inhibitors of prolyl 4-hydroxylase. The method comprises the administration of a prolyl 4-hydroxylase inhibitor to a patient. The inventors have shown that prolyl 4-hydroxlase inhibitors reduce muscle damage and preserve muscle function when administered prior to muscle damage in an in vivo assay for muscle function. Furthermore, the inventors have shown that when a prolyl 4-hydroxylase inhibitor is administered after muscle damage in the same assay, recovery of muscle function is enhanced.
PCT/US2013/042556 2012-05-24 2013-05-24 Treatment method WO2013177478A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261651364P 2012-05-24 2012-05-24
US61/651,364 2012-05-24
US201361759565P 2013-02-01 2013-02-01
US61/759,565 2013-02-01

Publications (2)

Publication Number Publication Date
WO2013177478A2 WO2013177478A2 (en) 2013-11-28
WO2013177478A3 true WO2013177478A3 (en) 2014-01-16

Family

ID=49624532

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/042556 WO2013177478A2 (en) 2012-05-24 2013-05-24 Treatment method

Country Status (1)

Country Link
WO (1) WO2013177478A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3906926A1 (en) * 2020-05-07 2021-11-10 Policlinico San Donato S.p.A.- Istituto di Ricovero e Cura a Carattere Scientifico Proline hydroxylase inhibitors for use in the skeletal muscle regeneration

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003095650A1 (en) * 2002-05-08 2003-11-20 Bayer Healthcare Ag Human prolyl 4-hydroxylase
WO2007082899A1 (en) * 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
WO2008040002A2 (en) * 2006-09-28 2008-04-03 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for hif modulating compounds
WO2011106226A2 (en) * 2010-02-23 2011-09-01 Cornell University Prolylhydroxylase inhibitors and methods of use
WO2011119887A1 (en) * 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Rna interference in dermal and fibrotic indications

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003095650A1 (en) * 2002-05-08 2003-11-20 Bayer Healthcare Ag Human prolyl 4-hydroxylase
WO2007082899A1 (en) * 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
WO2008040002A2 (en) * 2006-09-28 2008-04-03 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for hif modulating compounds
WO2011106226A2 (en) * 2010-02-23 2011-09-01 Cornell University Prolylhydroxylase inhibitors and methods of use
WO2011119887A1 (en) * 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Rna interference in dermal and fibrotic indications

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KHANNA ET AL.: "'Modalities in prevention of flexor tendon adhesion in the hand: What have we achieved so far ?", ACAT ORTHOPAEDICA BELGICA., vol. 75, August 2009 (2009-08-01), pages 433 - 444 *
MCCOMBE ET AL.: "A Collagen Prolyl 4-hydroxylase Inhibitor Reduces Adhesions after Tendon Injury.", CLINICAL ORTHOPAEDICS AND RELATED RESEARCH., vol. 451, October 2006 (2006-10-01), pages 251 - 256 *

Also Published As

Publication number Publication date
WO2013177478A2 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
ZA202208792B (en) Methods of treating and preventing graft versus host disease
WO2015095819A3 (en) Cancer treatment using combinations of erk and raf inhibitors
PH12015500407B1 (en) Methods of treating hypertriglyceridemia
WO2014062720A3 (en) Methods of treating cancer
WO2013024282A3 (en) Inhibitor or down- regulator of the expression of one or both of tbk1 ikk-epsilon for use in the treatment of pi3kinase dependent cancer
WO2012062925A3 (en) Compounds and methods for treating pain
WO2014004993A3 (en) Methods of reducing ldl-p
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
MX362626B (en) Methods of treating pediatric patients using dexmedetomidine.
WO2011123719A3 (en) Use of faah inhibitors for treating abdominal, visceral and pelvic pain
IN2014MN01227A (en)
MX354535B (en) Treatment of myocardial infarction using tgf - beta antagonists.
EP2513336A4 (en) Method for characterizing host immune function by ex vivo induction of offensive and defensive immune markers
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
WO2013010034A3 (en) Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
WO2013117744A3 (en) Methods of treating fibrosis
WO2015095838A3 (en) Cancer treatments using combinations of mek type i and erk inhibitors
MX2015015036A (en) Methods for improving lipid profiles using atrasentan.
CA3010788A1 (en) Methods of administering vasopressors
EA201590474A1 (en) PHARMACEUTICAL COMPOSITION BASED ON COMPOSITE CAPSULES INCLUDING IRBESARTAN AND HMG-COA REDUCTASE INHIBITOR
GB201022049D0 (en) Methods
WO2011163512A3 (en) Cancer therapy
MX348723B (en) Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder.
WO2013177478A3 (en) Treatment method
WO2014012025A3 (en) Igf-1 proteins and therapeutic uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13793185

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13793185

Country of ref document: EP

Kind code of ref document: A2